開拓藥業(09939.HK)普克魯胺治療新冠重症患者死亡風險降低92%
開拓藥業(09939.HK)表示,旗下普克魯胺治療COVID-19重症患者的臨床試驗結果顯示,普克魯胺於第14天達到主要終點,表明世界衛生組織COVID-19等級量表下由5.663的基線下降4.01至1.653。同時,結果顯示,普克魯胺可降低92%患者死亡風險(3.7%對比47.6%),並縮短住院時間中位數9天(住院時間中位數5天對比14天)。
臨床試驗設置男性及女性兩個隊列,每個隊列分為普克魯胺組及對照組兩個組別,最初招募588名符合所有資格標準的患者。在普克魯胺組中,患者將每日口服一次(QD) 300毫克普克魯胺,持續14天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.